Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13666952 | 0.77 | KDM4E (0.42) | BRAFKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL18256847 | 0.74 | KDM4E (0.42) | BRAFKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL9909693 | 0.73 | KDM4E (0.39) | BRAFKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL15935194 | 0.73 | KIF11 (0.40) | BRAFKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL22210785 | 0.73 | BRAF (0.41) | BRAFKDM4EALDH1A1HSD17B10 | |
| SCHEMBL15946957 | 0.69 | BRD4 (0.44) | BRAF | |
| SCHEMBL15935219 | 0.67 | KIF11 (0.40) | BRAFKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL9909761 | 0.66 | BRAF (0.52) | BRAF | |
| SCHEMBL15079240 | 0.65 | RXFP1 (0.36) | BRAFMAPT | |
| SCHEMBL10298653 | 0.64 | PDE3B (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710996-B2 | Pyrido-azaheterecydic compound and preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710996-B2 | Pyrido-azaheterecydic compound and preparation method and use thereof | MET, MERTK, DMPK | BRAF 13/4885KDM4E 217/4885ALDH1A1 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.